Release date: 2007-07-25 Minimally invasive interventional therapy for cardiovascular diseases has gained widespread popularity due to its low trauma, high effectiveness, fewer complications, no need for blood transfusions, shorter hospital stays, and the ability to be repeated. However, the high cost of imported stents—often reaching tens of thousands of dollars—has been a major barrier for many patients in China. Recently, a large-scale clinical trial demonstrated that high-quality domestic interventional devices are not only cost-effective but also deliver results that are just as reliable as their foreign counterparts. Since June of the previous year, a new biodegradable coating coronary stent developed domestically has been widely used across more than 50 hospitals in over 20 provinces. This initiative was led by the Department of Cardiology at the General Hospital of the Shenyang Military Region, involving a multi-center study with participation from three international heart centers in Indonesia, Malaysia, and Thailand. A total of 2,077 patients with coronary artery disease were treated using this new domestic drug-eluting stent. After six months of follow-up, the results showed a significant reduction in restenosis and stent thrombosis, with an overall success rate exceeding 98%. Compared to imported stents, the performance is nearly identical, but the cost is about 40% lower. These findings have been recognized globally, significantly enhancing the reputation of Chinese-made stents. According to official statistics, approximately 1.2 million children are born with birth defects each year in China, including around 150,000 with congenital heart disease. Professor Zhu Xianyang from the Department of Congenital Heart Disease noted that factors such as improper medication during pregnancy, viral infections, rubella, genetic predispositions, food contamination, and environmental influences have contributed to a rising incidence of congenital heart disease in Liaoning, affecting thousands of children annually. Early diagnosis and treatment are crucial, and the success rate of interventional surgery for these cases is as high as 98.5%. Historically, imported occluders used in treating congenital heart conditions were extremely expensive, preventing many children from receiving timely interventions. As a result, some went into adulthood without correction, missing their chance for surgery and facing lifelong challenges. In 2002, China made a breakthrough by developing domestic ventricular occlusion devices, atrial occlusion devices, and patent ductus arteriosus closures, completely breaking the reliance on imported products. The price of these domestic devices is about 60% of the imported ones. Over 3,000 domestic occluders have been successfully used in clinical settings, achieving a 98.8% success rate. Their quality is comparable to imported models, and they have provided relief to thousands of patients, helping them return to normal lives. ——Shanghai Medical Device Industry Association Organic Isomalto-Oligosaccharide 500 (corn) Powder Organic Corn IMO,Pure Corn Extract Powder,Instant Corn Powder Qingdao Bailong Huichuang Bio-tech Co., Ltd. , https://www.sdblcycn.com